E
Ultragenyx Pharmaceutical Inc.
RARE
$39.34
$0.090.23%
E
Sell
10/28/2024Downgrade
Ultragenyx Pharmaceutical Inc. (RARE) was downgraded to E+ from D- on 10/28/2024 due to a decline in the volatility index.
Ultragenyx Pharmaceutical Inc. (RARE) was downgraded to E+ from D- on 10/28/2024 due to a decline in the volatility index.
D
Sell
10/11/2024Upgraded
Ultragenyx Pharmaceutical Inc. (RARE) was upgraded to D- from E+ on 10/11/2024 due to an increase in the total return index and volatility index.
Ultragenyx Pharmaceutical Inc. (RARE) was upgraded to D- from E+ on 10/11/2024 due to an increase in the total return index and volatility index.
E
Sell
9/26/2024Downgrade
Ultragenyx Pharmaceutical Inc. (RARE) was downgraded to E+ from D- on 9/26/2024 due to a decline in the volatility index.
Ultragenyx Pharmaceutical Inc. (RARE) was downgraded to E+ from D- on 9/26/2024 due to a decline in the volatility index.
D
Sell
8/29/2024Upgraded
Ultragenyx Pharmaceutical Inc. (RARE) was upgraded to D- from E+ on 8/29/2024 due to an increase in the total return index, growth index and solvency index. Debt to equity declined from 6.45 to 2.08, operating cash flow increased 59.65% from -$190.73M to -$76.96M, and the quick ratio increased from 2.09 to 3.2.
Ultragenyx Pharmaceutical Inc. (RARE) was upgraded to D- from E+ on 8/29/2024 due to an increase in the total return index, growth index and solvency index. Debt to equity declined from 6.45 to 2.08, operating cash flow increased 59.65% from -$190.73M to -$76.96M, and the quick ratio increased from 2.09 to 3.2.
E
Sell
3/14/2023Downgrade
Ultragenyx Pharmaceutical Inc. (RARE) was downgraded to E+ from D on 3/14/2023 due to a decline in the volatility index and solvency index. The quick ratio declined from 4.06 to 3.04.
Ultragenyx Pharmaceutical Inc. (RARE) was downgraded to E+ from D on 3/14/2023 due to a decline in the volatility index and solvency index. The quick ratio declined from 4.06 to 3.04.
D
Sell
2/9/2023Upgraded
Ultragenyx Pharmaceutical Inc. (RARE) was upgraded to D from E+ on 2/9/2023 due to an increase in the volatility index.
Ultragenyx Pharmaceutical Inc. (RARE) was upgraded to D from E+ on 2/9/2023 due to an increase in the volatility index.
E
Sell
2/8/2023Downgrade
Ultragenyx Pharmaceutical Inc. (RARE) was downgraded to E+ from D on 02/08/2023.
Ultragenyx Pharmaceutical Inc. (RARE) was downgraded to E+ from D on 02/08/2023.
D
Sell
2/1/2023Upgraded
Ultragenyx Pharmaceutical Inc. (RARE) was upgraded to D from D- on 2/1/2023 due to an increase in the total return index and volatility index.
Ultragenyx Pharmaceutical Inc. (RARE) was upgraded to D from D- on 2/1/2023 due to an increase in the total return index and volatility index.
D
Sell
11/4/2022Downgrade
Ultragenyx Pharmaceutical Inc. (RARE) was downgraded to D- from D on 11/4/2022 due to a decline in the growth index, solvency index and total return index. EBIT declined 58.95% from -$141.59M to -$225.07M, earnings per share declined from -$2.2619 to -$3.5, and debt to equity increased from 0.02 to 0.03.
Ultragenyx Pharmaceutical Inc. (RARE) was downgraded to D- from D on 11/4/2022 due to a decline in the growth index, solvency index and total return index. EBIT declined 58.95% from -$141.59M to -$225.07M, earnings per share declined from -$2.2619 to -$3.5, and debt to equity increased from 0.02 to 0.03.
D
Sell
9/1/2022Upgraded
Ultragenyx Pharmaceutical Inc. (RARE) was upgraded to D from D- on 9/1/2022 due to an increase in the volatility index and total return index.
Ultragenyx Pharmaceutical Inc. (RARE) was upgraded to D from D- on 9/1/2022 due to an increase in the volatility index and total return index.
D
Sell
8/16/2022Downgrade
Ultragenyx Pharmaceutical Inc. (RARE) was downgraded to D- from D on 8/16/2022 due to a decline in the volatility index and total return index.
Ultragenyx Pharmaceutical Inc. (RARE) was downgraded to D- from D on 8/16/2022 due to a decline in the volatility index and total return index.
D
Sell
7/29/2022Upgraded
Ultragenyx Pharmaceutical Inc. (RARE) was upgraded to D from D- on 7/29/2022 due to an increase in the growth index and volatility index. Operating cash flow increased 34.26% from -$117.52M to -$77.26M, and total revenue increased 11.77% from $79.94M to $89.34M.
Ultragenyx Pharmaceutical Inc. (RARE) was upgraded to D from D- on 7/29/2022 due to an increase in the growth index and volatility index. Operating cash flow increased 34.26% from -$117.52M to -$77.26M, and total revenue increased 11.77% from $79.94M to $89.34M.
D
Sell
7/19/2022Downgrade
Ultragenyx Pharmaceutical Inc. (RARE) was downgraded to D- from D on 7/19/2022 due to a large decline in the total return index and volatility index.
Ultragenyx Pharmaceutical Inc. (RARE) was downgraded to D- from D on 7/19/2022 due to a large decline in the total return index and volatility index.
D
Sell
5/16/2022Upgraded
Ultragenyx Pharmaceutical Inc. (RARE) was upgraded to D from E+ on 5/16/2022 due to an increase in the volatility index.
Ultragenyx Pharmaceutical Inc. (RARE) was upgraded to D from E+ on 5/16/2022 due to an increase in the volatility index.
E
Sell
5/13/2022Downgrade
Ultragenyx Pharmaceutical Inc. (RARE) was downgraded to E+ from D on 5/13/2022 due to a decline in the solvency index, volatility index and growth index. Operating cash flow declined 116.25% from -$54.34M to -$117.52M, EBIT declined 33.22% from -$102.56M to -$136.63M, and earnings per share declined from -$1.7859 to -$2.1911.
Ultragenyx Pharmaceutical Inc. (RARE) was downgraded to E+ from D on 5/13/2022 due to a decline in the solvency index, volatility index and growth index. Operating cash flow declined 116.25% from -$54.34M to -$117.52M, EBIT declined 33.22% from -$102.56M to -$136.63M, and earnings per share declined from -$1.7859 to -$2.1911.
D
Sell
5/5/2022Upgraded
Ultragenyx Pharmaceutical Inc. (RARE) was upgraded to D from D- on 5/5/2022 due to an increase in the total return index and valuation index.
Ultragenyx Pharmaceutical Inc. (RARE) was upgraded to D from D- on 5/5/2022 due to an increase in the total return index and valuation index.
D
Sell
4/20/2022Downgrade
Ultragenyx Pharmaceutical Inc. (RARE) was downgraded to D- from D on 4/20/2022 due to a noticeable decline in the solvency index, growth index and total return index. Earnings per share declined from -$1.0755 to -$1.7859, the quick ratio declined from 5.64 to 4.33, and EBIT declined 14.18% from -$89.83M to -$102.56M.
Ultragenyx Pharmaceutical Inc. (RARE) was downgraded to D- from D on 4/20/2022 due to a noticeable decline in the solvency index, growth index and total return index. Earnings per share declined from -$1.0755 to -$1.7859, the quick ratio declined from 5.64 to 4.33, and EBIT declined 14.18% from -$89.83M to -$102.56M.
D
Sell
11/23/2021Upgraded
Ultragenyx Pharmaceutical Inc. (RARE) was upgraded to D from D- on 11/23/2021 due to an increase in the volatility index and valuation index.
Ultragenyx Pharmaceutical Inc. (RARE) was upgraded to D from D- on 11/23/2021 due to an increase in the volatility index and valuation index.
D
Sell
11/8/2021Downgrade
Ultragenyx Pharmaceutical Inc. (RARE) was downgraded to D- from D on 11/8/2021 due to a decline in the valuation index.
Ultragenyx Pharmaceutical Inc. (RARE) was downgraded to D- from D on 11/8/2021 due to a decline in the valuation index.
D
Sell
5/1/2020Upgraded
Ultragenyx Pharmaceutical Inc. (RARE) was upgraded to D from D- on 5/1/2020 due to an increase in the total return index, volatility index and growth index. Total revenue increased 37.96% from $25.8M to $35.59M, EBIT increased 19.98% from -$118.03M to -$94.45M, and operating cash flow increased 18.61% from -$88.51M to -$72.04M.
Ultragenyx Pharmaceutical Inc. (RARE) was upgraded to D from D- on 5/1/2020 due to an increase in the total return index, volatility index and growth index. Total revenue increased 37.96% from $25.8M to $35.59M, EBIT increased 19.98% from -$118.03M to -$94.45M, and operating cash flow increased 18.61% from -$88.51M to -$72.04M.
D
Sell
11/12/2019Downgrade
Ultragenyx Pharmaceutical Inc. (RARE) was downgraded to D- from D on 11/12/2019 due to a noticeable decline in the total return index, growth index and volatility index. Earnings per share declined from -$1.7242 to -$1.958, and EBIT declined 4.94% from -$112.47M to -$118.03M.
Ultragenyx Pharmaceutical Inc. (RARE) was downgraded to D- from D on 11/12/2019 due to a noticeable decline in the total return index, growth index and volatility index. Earnings per share declined from -$1.7242 to -$1.958, and EBIT declined 4.94% from -$112.47M to -$118.03M.
D
Sell
4/10/2019Upgraded
Ultragenyx Pharmaceutical Inc. (RARE) was upgraded to D from D- on 4/10/2019 due to a noticeable increase in the growth index, total return index and volatility index. Total revenue increased 38.24% from $11.76M to $16.26M, operating cash flow increased 19.24% from -$69.16M to -$55.85M, and earnings per share increased from -$1.7351 to -$1.7325.
Ultragenyx Pharmaceutical Inc. (RARE) was upgraded to D from D- on 4/10/2019 due to a noticeable increase in the growth index, total return index and volatility index. Total revenue increased 38.24% from $11.76M to $16.26M, operating cash flow increased 19.24% from -$69.16M to -$55.85M, and earnings per share increased from -$1.7351 to -$1.7325.
D
Sell
1/7/2019Downgrade
Ultragenyx Pharmaceutical Inc. (RARE) was downgraded to D- from D on 1/7/2019 due to a large decline in the growth index, solvency index and efficiency index. Net income declined 65.59% from -$52.73M to -$87.31M, earnings per share declined from -$1.0584 to -$1.7351, and total revenue declined 8.06% from $12.79M to $11.76M.
Ultragenyx Pharmaceutical Inc. (RARE) was downgraded to D- from D on 1/7/2019 due to a large decline in the growth index, solvency index and efficiency index. Net income declined 65.59% from -$52.73M to -$87.31M, earnings per share declined from -$1.0584 to -$1.7351, and total revenue declined 8.06% from $12.79M to $11.76M.
D
Sell
5/11/2018Upgraded
Ultragenyx Pharmaceutical Inc. (RARE) was upgraded to D from D- on 5/11/2018 due to a substantial increase in the growth index, efficiency index and valuation index. Total revenue increased 342.29% from $2.41M to $10.68M, net income increased 137.02% from -$81.73M to $30.25M, and earnings per share increased from -$1.8947 to $0.62.
Ultragenyx Pharmaceutical Inc. (RARE) was upgraded to D from D- on 5/11/2018 due to a substantial increase in the growth index, efficiency index and valuation index. Total revenue increased 342.29% from $2.41M to $10.68M, net income increased 137.02% from -$81.73M to $30.25M, and earnings per share increased from -$1.8947 to $0.62.
D
Sell
6/12/2017Downgrade
Ultragenyx Pharmaceutical Inc. (RARE) was downgraded to D- from D on 6/12/2017 due to a decline in the total return index and volatility index.
Ultragenyx Pharmaceutical Inc. (RARE) was downgraded to D- from D on 6/12/2017 due to a decline in the total return index and volatility index.
D
Sell
5/22/2017Upgraded
Ultragenyx Pharmaceutical Inc. (RARE) was upgraded to D from D- on 5/22/2017 due to an increase in the solvency index and volatility index. The quick ratio increased from 6.31 to 8.22.
Ultragenyx Pharmaceutical Inc. (RARE) was upgraded to D from D- on 5/22/2017 due to an increase in the solvency index and volatility index. The quick ratio increased from 6.31 to 8.22.
D
Sell
5/2/2017Downgrade
Ultragenyx Pharmaceutical Inc. (RARE) was downgraded to D- from D on 5/2/2017 due to a decline in the total return index and volatility index.
Ultragenyx Pharmaceutical Inc. (RARE) was downgraded to D- from D on 5/2/2017 due to a decline in the total return index and volatility index.
D
Sell
3/31/2017Upgraded
Ultragenyx Pharmaceutical Inc. (RARE) was upgraded to D from D- on 3/31/2017 due to an increase in the total return index, volatility index and valuation index.
Ultragenyx Pharmaceutical Inc. (RARE) was upgraded to D from D- on 3/31/2017 due to an increase in the total return index, volatility index and valuation index.
D
Sell
2/17/2017Downgrade
Ultragenyx Pharmaceutical Inc. (RARE) was downgraded to D- from D on 2/17/2017 due to a noticeable decline in the volatility index, total return index and efficiency index. Net income declined 9.83% from -$64.91M to -$71.29M.
Ultragenyx Pharmaceutical Inc. (RARE) was downgraded to D- from D on 2/17/2017 due to a noticeable decline in the volatility index, total return index and efficiency index. Net income declined 9.83% from -$64.91M to -$71.29M.
D
Sell
3/2/2016Downgrade
Ultragenyx Pharmaceutical Inc. (RARE) was downgraded to D from D+ on 3/2/2016 due to a significant decline in the volatility index, efficiency index and total return index. Total capital declined 7.92% from $576.76M to $531.09M.
Ultragenyx Pharmaceutical Inc. (RARE) was downgraded to D from D+ on 3/2/2016 due to a significant decline in the volatility index, efficiency index and total return index. Total capital declined 7.92% from $576.76M to $531.09M.
D
Sell
5/14/2015Upgraded
Ultragenyx Pharmaceutical Inc. (RARE) was upgraded to D+ from D on 5/14/2015 due to a significant increase in the volatility index, total return index and efficiency index. Total capital increased 84.44% from $184.95M to $341.12M, and net income increased 27.73% from -$16.74M to -$21.38M.
Ultragenyx Pharmaceutical Inc. (RARE) was upgraded to D+ from D on 5/14/2015 due to a significant increase in the volatility index, total return index and efficiency index. Total capital increased 84.44% from $184.95M to $341.12M, and net income increased 27.73% from -$16.74M to -$21.38M.
D
Sell
11/14/2014Downgrade
Ultragenyx Pharmaceutical Inc. (RARE) was downgraded to D from D+ on 11/14/2014 due to a decline in the growth index and efficiency index.
Ultragenyx Pharmaceutical Inc. (RARE) was downgraded to D from D+ on 11/14/2014 due to a decline in the growth index and efficiency index.
D
Sell
8/29/2014Upgraded
Ultragenyx Pharmaceutical Inc. (RARE) was upgraded to D+ from D on 8/29/2014 due to a noticeable increase in the total return index, growth index and volatility index. EBIT increased 32.13% from -$10.34M to -$13.66M, and operating cash flow increased 26.31% from -$8.34M to -$10.53M.
Ultragenyx Pharmaceutical Inc. (RARE) was upgraded to D+ from D on 8/29/2014 due to a noticeable increase in the total return index, growth index and volatility index. EBIT increased 32.13% from -$10.34M to -$13.66M, and operating cash flow increased 26.31% from -$8.34M to -$10.53M.
D
Sell
7/1/2014Upgraded
Ultragenyx Pharmaceutical Inc. (RARE) was upgraded to D from E- on 07/01/2014.
Ultragenyx Pharmaceutical Inc. (RARE) was upgraded to D from E- on 07/01/2014.
E
Sell
6/30/2014Downgrade
Ultragenyx Pharmaceutical Inc. (RARE) was downgraded to E- from D on 6/30/2014 due to a large decline in the total return index and valuation index.
Ultragenyx Pharmaceutical Inc. (RARE) was downgraded to E- from D on 6/30/2014 due to a large decline in the total return index and valuation index.
D
Sell
5/16/2014Upgraded
Ultragenyx Pharmaceutical Inc. (RARE) was upgraded to D from on 5/16/2014 due to a significant increase in the solvency index, total return index and volatility index. The quick ratio increased from 9.01 to 24.28.
Ultragenyx Pharmaceutical Inc. (RARE) was upgraded to D from on 5/16/2014 due to a significant increase in the solvency index, total return index and volatility index. The quick ratio increased from 9.01 to 24.28.
NASDAQ
03/14/2025 4:00PM Eastern
Quotes delayed
